Note: Novavax's revenues are gauged from an analysis of company filings.
Trademark applications show the products and services that Novavax is developing and marketing.
Novavax's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
WE FOCUS ON THIS SO THEY CAN FOCUS ON THAT pharmaceutical, biologic, and vaccine research and development; consulting services in the field of research and development of pharmaceutical, biologic, and vaccine preparations and adjuvants; providing medical and scientific research information in the field of pharmaceuticals, biologics, and vaccines, and clinical trials and post-market trials related to pharmaceuticals, biologics, and vaccines
CREATING TOMORROW'S VACCINES TODAY Pharmaceutical preparations for the treatment of infectious diseases; vaccines; adjuvants
Determine whether Novavax grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Novavax is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
A competitive analysis shows these companies are in the same general field as Novavax, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are in the same general field as Novavax and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.